Activation of Rho is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor Receptor

Julie L. Boerner, Andrew Danielsen, Michael J. McManus, Nita J. Maihle

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Mutations in the epidermal growth factor receptor have been identified in several human tumor types, including gliomas. These receptor mutants have deletions in their extracellular ligand-binding domains and are, therefore, no longer regulated by ligand, resulting in constitutive activation of the receptor kinase. These mutants have been proposed to transduce oncogenic signals via ligand-independent signaling pathways. Avian viral homologues of these oncogenic epidermal growth factor receptors exhibit structurally homologous deletions and form tumors in chickens. One such mutant, S3v-ErbB, transforms fibroblasts in vitro, and transformation has been correlated with the formation of a novel tyrosine phosphoprotein complex. V-ErbB-mediated complex formation and transformation have been shown to occur independently of Ras activation. The major aims of this study are to further characterize this ligand-independent v-ErbB oncogenic signaling pathway. Here we show that both v-ErbB-mediated phosphoprotein complex formation and transformation are inhibited by a dominant negative mutant of Rho. This inhibition is specific for dominant negative Rho; dominant negative mutants of Rac and Cdc42 have no effect on transformation or on tyrosine phosphorylation of the phosphoprotein complex. Based on these observations, we propose that S3v-ErbB stimulates a Rho-dependent tyrosine kinase, resulting in complex formation and ultimately oncogenic transformation.

Original languageEnglish (US)
Pages (from-to)3691-3695
Number of pages5
JournalJournal of Biological Chemistry
Volume276
Issue number5
DOIs
StatePublished - Feb 2 2001
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Phosphoproteins
Chemical activation
Ligands
Tyrosine
Tumors
Phosphorylation
Fibroblasts
Glioma
Protein-Tyrosine Kinases
Chickens
Neoplasms
Phosphotransferases
Mutation

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Activation of Rho is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor Receptor. / Boerner, Julie L.; Danielsen, Andrew; McManus, Michael J.; Maihle, Nita J.

In: Journal of Biological Chemistry, Vol. 276, No. 5, 02.02.2001, p. 3691-3695.

Research output: Contribution to journalArticle

Boerner, Julie L. ; Danielsen, Andrew ; McManus, Michael J. ; Maihle, Nita J. / Activation of Rho is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor Receptor. In: Journal of Biological Chemistry. 2001 ; Vol. 276, No. 5. pp. 3691-3695.
@article{dc3e6fd5c08442d395a6003399517399,
title = "Activation of Rho is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor Receptor",
abstract = "Mutations in the epidermal growth factor receptor have been identified in several human tumor types, including gliomas. These receptor mutants have deletions in their extracellular ligand-binding domains and are, therefore, no longer regulated by ligand, resulting in constitutive activation of the receptor kinase. These mutants have been proposed to transduce oncogenic signals via ligand-independent signaling pathways. Avian viral homologues of these oncogenic epidermal growth factor receptors exhibit structurally homologous deletions and form tumors in chickens. One such mutant, S3v-ErbB, transforms fibroblasts in vitro, and transformation has been correlated with the formation of a novel tyrosine phosphoprotein complex. V-ErbB-mediated complex formation and transformation have been shown to occur independently of Ras activation. The major aims of this study are to further characterize this ligand-independent v-ErbB oncogenic signaling pathway. Here we show that both v-ErbB-mediated phosphoprotein complex formation and transformation are inhibited by a dominant negative mutant of Rho. This inhibition is specific for dominant negative Rho; dominant negative mutants of Rac and Cdc42 have no effect on transformation or on tyrosine phosphorylation of the phosphoprotein complex. Based on these observations, we propose that S3v-ErbB stimulates a Rho-dependent tyrosine kinase, resulting in complex formation and ultimately oncogenic transformation.",
author = "Boerner, {Julie L.} and Andrew Danielsen and McManus, {Michael J.} and Maihle, {Nita J.}",
year = "2001",
month = "2",
day = "2",
doi = "10.1074/jbc.M003801200",
language = "English (US)",
volume = "276",
pages = "3691--3695",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "5",

}

TY - JOUR

T1 - Activation of Rho is Required for Ligand-independent Oncogenic Signaling by a Mutant Epidermal Growth Factor Receptor

AU - Boerner, Julie L.

AU - Danielsen, Andrew

AU - McManus, Michael J.

AU - Maihle, Nita J.

PY - 2001/2/2

Y1 - 2001/2/2

N2 - Mutations in the epidermal growth factor receptor have been identified in several human tumor types, including gliomas. These receptor mutants have deletions in their extracellular ligand-binding domains and are, therefore, no longer regulated by ligand, resulting in constitutive activation of the receptor kinase. These mutants have been proposed to transduce oncogenic signals via ligand-independent signaling pathways. Avian viral homologues of these oncogenic epidermal growth factor receptors exhibit structurally homologous deletions and form tumors in chickens. One such mutant, S3v-ErbB, transforms fibroblasts in vitro, and transformation has been correlated with the formation of a novel tyrosine phosphoprotein complex. V-ErbB-mediated complex formation and transformation have been shown to occur independently of Ras activation. The major aims of this study are to further characterize this ligand-independent v-ErbB oncogenic signaling pathway. Here we show that both v-ErbB-mediated phosphoprotein complex formation and transformation are inhibited by a dominant negative mutant of Rho. This inhibition is specific for dominant negative Rho; dominant negative mutants of Rac and Cdc42 have no effect on transformation or on tyrosine phosphorylation of the phosphoprotein complex. Based on these observations, we propose that S3v-ErbB stimulates a Rho-dependent tyrosine kinase, resulting in complex formation and ultimately oncogenic transformation.

AB - Mutations in the epidermal growth factor receptor have been identified in several human tumor types, including gliomas. These receptor mutants have deletions in their extracellular ligand-binding domains and are, therefore, no longer regulated by ligand, resulting in constitutive activation of the receptor kinase. These mutants have been proposed to transduce oncogenic signals via ligand-independent signaling pathways. Avian viral homologues of these oncogenic epidermal growth factor receptors exhibit structurally homologous deletions and form tumors in chickens. One such mutant, S3v-ErbB, transforms fibroblasts in vitro, and transformation has been correlated with the formation of a novel tyrosine phosphoprotein complex. V-ErbB-mediated complex formation and transformation have been shown to occur independently of Ras activation. The major aims of this study are to further characterize this ligand-independent v-ErbB oncogenic signaling pathway. Here we show that both v-ErbB-mediated phosphoprotein complex formation and transformation are inhibited by a dominant negative mutant of Rho. This inhibition is specific for dominant negative Rho; dominant negative mutants of Rac and Cdc42 have no effect on transformation or on tyrosine phosphorylation of the phosphoprotein complex. Based on these observations, we propose that S3v-ErbB stimulates a Rho-dependent tyrosine kinase, resulting in complex formation and ultimately oncogenic transformation.

UR - http://www.scopus.com/inward/record.url?scp=0035793618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035793618&partnerID=8YFLogxK

U2 - 10.1074/jbc.M003801200

DO - 10.1074/jbc.M003801200

M3 - Article

VL - 276

SP - 3691

EP - 3695

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 5

ER -